JP2019536750A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536750A5 JP2019536750A5 JP2019518499A JP2019518499A JP2019536750A5 JP 2019536750 A5 JP2019536750 A5 JP 2019536750A5 JP 2019518499 A JP2019518499 A JP 2019518499A JP 2019518499 A JP2019518499 A JP 2019518499A JP 2019536750 A5 JP2019536750 A5 JP 2019536750A5
- Authority
- JP
- Japan
- Prior art keywords
- nhr
- independently
- nhc
- infection
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 106
- 229920006395 saturated elastomer Polymers 0.000 claims description 44
- 125000000217 alkyl group Chemical group 0.000 claims description 34
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 28
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- 241000894006 Bacteria Species 0.000 claims description 18
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 208000003476 primary myelofibrosis Diseases 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 239000012453 solvate Substances 0.000 claims description 11
- 125000002947 alkylene group Chemical group 0.000 claims description 10
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 claims description 9
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 150000004677 hydrates Chemical class 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- -1 piperidino, piperazino, morpholino Chemical group 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 6
- LQOINZORMUUALB-UHFFFAOYSA-N N1(CCCC1)C1(N(CCOC1)N1CCNCC1)N1CCCCC1 Chemical compound N1(CCCC1)C1(N(CCOC1)N1CCNCC1)N1CCCCC1 LQOINZORMUUALB-UHFFFAOYSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 208000022760 infectious otitis media Diseases 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 125000003375 sulfoxide group Chemical group 0.000 claims description 6
- 125000004434 sulfur atom Chemical group 0.000 claims description 6
- 208000035143 Bacterial infection Diseases 0.000 claims description 5
- 230000001668 ameliorated effect Effects 0.000 claims description 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 206010060968 Arthritis infective Diseases 0.000 claims description 3
- 206010051548 Burn infection Diseases 0.000 claims description 3
- 208000014912 Central Nervous System Infections Diseases 0.000 claims description 3
- 206010014666 Endocarditis bacterial Diseases 0.000 claims description 3
- 208000001860 Eye Infections Diseases 0.000 claims description 3
- 206010017964 Gastrointestinal infection Diseases 0.000 claims description 3
- 206010061977 Genital infection female Diseases 0.000 claims description 3
- 208000036209 Intraabdominal Infections Diseases 0.000 claims description 3
- 206010024971 Lower respiratory tract infections Diseases 0.000 claims description 3
- 206010031252 Osteomyelitis Diseases 0.000 claims description 3
- 206010033078 Otitis media Diseases 0.000 claims description 3
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 206010046306 Upper respiratory tract infection Diseases 0.000 claims description 3
- 208000009361 bacterial endocarditis Diseases 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 208000019836 digestive system infectious disease Diseases 0.000 claims description 3
- 208000011323 eye infectious disease Diseases 0.000 claims description 3
- 201000007119 infective endocarditis Diseases 0.000 claims description 3
- 210000004400 mucous membrane Anatomy 0.000 claims description 3
- 206010033072 otitis externa Diseases 0.000 claims description 3
- 201000009890 sinusitis Diseases 0.000 claims description 3
- 208000000143 urethritis Diseases 0.000 claims description 3
- 206010048685 Oral infection Diseases 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 206010061393 typhus Diseases 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000606697 Rickettsia prowazekii Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1617064.9 | 2016-10-07 | ||
| GBGB1617064.9A GB201617064D0 (en) | 2016-10-07 | 2016-10-07 | Compounds and their therapeutic use |
| PCT/EP2017/075567 WO2018065611A1 (en) | 2016-10-07 | 2017-10-06 | 2-amino-n-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-trna synthetase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019536750A JP2019536750A (ja) | 2019-12-19 |
| JP2019536750A5 true JP2019536750A5 (https=) | 2020-11-05 |
| JP6906608B2 JP6906608B2 (ja) | 2021-07-21 |
Family
ID=57610498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518499A Active JP6906608B2 (ja) | 2016-10-07 | 2017-10-06 | 細菌アミノアシル−ｔＲＮＡシンセターゼの阻害剤としての２−アミノ−Ｎ−（アリールスルフィニル）−アセトアミド化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11802110B2 (https=) |
| EP (1) | EP3523282A1 (https=) |
| JP (1) | JP6906608B2 (https=) |
| KR (1) | KR102437676B1 (https=) |
| CN (1) | CN110049970B (https=) |
| AU (1) | AU2017339104B2 (https=) |
| CA (1) | CA3038892C (https=) |
| EA (1) | EA201990855A1 (https=) |
| GB (1) | GB201617064D0 (https=) |
| IL (1) | IL265790B2 (https=) |
| MA (1) | MA46449A (https=) |
| MX (1) | MX388072B (https=) |
| WO (1) | WO2018065611A1 (https=) |
| ZA (1) | ZA201902765B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA036995B1 (ru) * | 2015-02-13 | 2021-01-25 | Оксфорд Драг Дизайн Лимитед | НОВЫЕ N-АЦИЛАРИЛСУЛЬФОНАМИДНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ АМИНОАЦИЛ-тРНК СИНТЕТАЗЫ |
| GB201617064D0 (en) | 2016-10-07 | 2016-11-23 | Inhibox Limited And Latvian Institute Of Organic Synthesis The | Compounds and their therapeutic use |
| CN110642758A (zh) * | 2019-09-05 | 2020-01-03 | 浙江杰上杰新材料有限公司 | 一种对甲苯磺酰氨基脲发泡剂的合成方法 |
| CN110642760A (zh) * | 2019-09-05 | 2020-01-03 | 浙江杰上杰新材料有限公司 | 一种对甲苯亚磺酸锌的合成方法 |
| CN110642759A (zh) * | 2019-09-05 | 2020-01-03 | 浙江杰上杰新材料有限公司 | 一种苯亚磺酸锌的合成方法 |
| MX2022007500A (es) * | 2019-12-19 | 2022-07-04 | Oxford Drug Design Ltd | Compuestos de 2-amino-n-(amino-oxo-aril-lambda6-sulfanilideno)acet amida y su uso terapeutico. |
| WO2025108986A1 (en) | 2023-11-21 | 2025-05-30 | Oxford Drug Design Limited | 2-amino-n-(oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use |
| CN117510380B (zh) * | 2024-01-08 | 2024-04-05 | 寿光诺盟化工有限公司 | 一种苯磺酸酯的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05208914A (ja) | 1991-09-03 | 1993-08-20 | Fujisawa Pharmaceut Co Ltd | ペプチド化合物を含有する医薬組成物 |
| US5824657A (en) | 1997-03-18 | 1998-10-20 | Cubist Pharmaceuticals, Inc. | Aminoacyl sulfamides for the treatment of hyperproliferative disorders |
| US20020052370A1 (en) | 2000-07-06 | 2002-05-02 | Barber Christopher Gordon | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
| US7183320B2 (en) | 2001-06-06 | 2007-02-27 | Eli Lilly And Company | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents |
| WO2005037860A2 (en) | 2003-10-10 | 2005-04-28 | Vertex Pharmaceuticals Incoporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| ZA200602937B (en) | 2003-10-10 | 2007-06-27 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| JP2013522274A (ja) | 2010-03-18 | 2013-06-13 | バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー | 非生物的な植物ストレスに対する活性剤としてのアリールスルホンアミド類及びヘタリールスルホンアミド類 |
| AR091858A1 (es) | 2012-07-25 | 2015-03-04 | Sova Pharmaceuticals Inc | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) |
| EA036995B1 (ru) | 2015-02-13 | 2021-01-25 | Оксфорд Драг Дизайн Лимитед | НОВЫЕ N-АЦИЛАРИЛСУЛЬФОНАМИДНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ АМИНОАЦИЛ-тРНК СИНТЕТАЗЫ |
| CN105198789B (zh) | 2015-10-26 | 2018-06-05 | 山东大学 | 取代3-吲哚类Bcl-2蛋白抑制剂及制备方法和应用 |
| CN109152368A (zh) | 2016-03-15 | 2019-01-04 | 拜耳作物科学股份公司 | 用于防治动物害虫的取代的磺酰胺 |
| GB201617064D0 (en) | 2016-10-07 | 2016-11-23 | Inhibox Limited And Latvian Institute Of Organic Synthesis The | Compounds and their therapeutic use |
-
2016
- 2016-10-07 GB GBGB1617064.9A patent/GB201617064D0/en not_active Ceased
-
2017
- 2017-10-06 CA CA3038892A patent/CA3038892C/en active Active
- 2017-10-06 CN CN201780074911.0A patent/CN110049970B/zh active Active
- 2017-10-06 MA MA046449A patent/MA46449A/fr unknown
- 2017-10-06 EP EP17780426.7A patent/EP3523282A1/en active Pending
- 2017-10-06 KR KR1020197012665A patent/KR102437676B1/ko active Active
- 2017-10-06 AU AU2017339104A patent/AU2017339104B2/en active Active
- 2017-10-06 JP JP2019518499A patent/JP6906608B2/ja active Active
- 2017-10-06 US US16/339,542 patent/US11802110B2/en active Active
- 2017-10-06 EA EA201990855A patent/EA201990855A1/ru unknown
- 2017-10-06 MX MX2019004001A patent/MX388072B/es unknown
- 2017-10-06 WO PCT/EP2017/075567 patent/WO2018065611A1/en not_active Ceased
-
2019
- 2019-04-03 IL IL265790A patent/IL265790B2/en unknown
- 2019-05-02 ZA ZA2019/02765A patent/ZA201902765B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019536750A5 (https=) | ||
| JP2010530372A5 (https=) | ||
| ES2442167T3 (es) | Nuevos agentes antibacterianos para el tratamiento de infecciones gram positivas | |
| WO2014176636A9 (en) | Compounds and methods of treating infections | |
| CN103781787A (zh) | 含氮化合物及其用途 | |
| KR100893426B1 (ko) | 항균 활성을 갖는 플레우로무틸린 유도체 | |
| ES2186550B2 (es) | Nuevos derivados de oxazolidinonas como antibacterianos. | |
| MX2007011105A (es) | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos. | |
| CN106660962A (zh) | 用作选择性抗菌剂的含2‑吡啶酮部分的芳基酰肼 | |
| ES2699001T3 (es) | Nuevo compuesto antibacteriano de oxazolidinona | |
| JP6411482B2 (ja) | 窒素含有化合物およびその使用 | |
| HUP0303457A2 (hu) | Antimikrobiális hatású 2-piridonok, ezeket tartalmazó készítmények és alkalmazásuk | |
| GB2123828A (en) | C-23-modified derivatives of omt | |
| JP2010511669A5 (https=) | ||
| JPH0645627B2 (ja) | β−ラクタム化合物、その製造方法および薬剤 | |
| TW519542B (en) | Bicyclic amine derivative | |
| KR20150045513A (ko) | 3환식 테트라하이드로퀴놀린 항박테리아제 | |
| CN104844628A (zh) | 2H,6H-嘧啶并[2,1-b][1,3]噻嗪类衍生物及其应用 | |
| HU184793B (en) | Process for preparing new 7-/4-hydroxy-3-pyrimidinyl/-ureido/-acetamido-3-methyl-cef-3-em-4-carboxylic acid derivatives | |
| BRPI0614099A2 (pt) | uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto e o referido composto | |
| JP2023506894A5 (https=) | ||
| RU2634122C1 (ru) | Фторхинолоны на основе 4-дезоксипиридоксина | |
| Lee et al. | Synthesis and antibacterial activities of novel C (3)-aminopyrimidinyl substituted cephalosporins including against respiratory tract pathogens | |
| JP2005531603A5 (https=) | ||
| JPWO2005073238A1 (ja) | ピリドベンズオキサジン誘導体 |